Alzheimer’s global license has this tiny cap launching

Today’s big movers inside                                                                                                                                                                                                                                                                                                                                                                                                                 July 16, 2024 | [Read Online]( Alzheimer’s global license has this tiny cap launching *together with Brooks Enterprises Good morning, 360! Don’t forget to join us today for LIVE trading in the [Market Master’s Room]( — as well as for DAY #2 in Options Bootcamp TONIGHT at 7pm EST (invite a friend 👯). Be the best prepared traders on the Street! FOCUS LIST🔎 SILO - Up over 100% in the pre-market after securing exclusive global license for Alzheimer's Therapeutic CDT - Up over 50% in pre after receiving patent approval for its lead asset targeting autoimmune diseases *together with Brooks Enterprises Can an AI trading bot hunt for the best trades 24 hours a day?  Stephen Brooks says YES with his Trade Fusion system. [Register here for his LIVE webinar Thursday, July 18th @ 7pm EST]( Once you register, you’ll receive THIS sneak peak: *[AI Trading Bot Explained]( 🤖 HOTLIST🔥 SILO - Up over 100% in pre after securing exclusive global license for Alzheimer's Therapeutic Silo Pharma Inc. (SILO) operates as a developmental stage biopharmaceutical company. The company is developing therapeutics that address underserved conditions, including stress-induced psychiatric disorders, chronic pain conditions, and central nervous system (CNS) diseases. In the pre-market this morning the [company announced]( that it has entered into an exclusive global license agreement to further develop, manufacture, and commercialize its Alzheimer’s drug SPC-14. Silo intends to utilize the FDA’s streamlined 505(b)(2) pathway for SPC-14, which would shorten clinical timelines and reduce drug development costs. “In our view, our exclusive license for SPC-14 gives us the potential to meet a large unmet medical need. If approved, we believe SPC-14 could bring hope and relief for many families and patients. Early pre-clinical studies have shown stress reduction and cognitive improvement,” said Silo CEO Eric Weisblum. The stock traded up over 60% in the pre-market in reaction to the news. The first target for bulls is the pre-market high $2.52. Beyond that, $2.57, $2.86, $3.05, $3.40 and $3.98 come into play. Below $2.52, targets to the downside are $2.25, $2.08, $1.80, $1.60, $1.40, $1.20 and then a gap fill at $1.07. CDT - Up over 50% in pre after receiving patent approval for its lead asset targeting autoimmune diseases Conduit Pharmaceuticals Inc. (CDT) is a clinical-stage specialty biopharmaceutical company that develops pharmaceutical products that provides unmet medical needs in the areas of autoimmune diseases and idiopathic male infertility. In the pre-market the [company announced]( the approval of a composition of matter patent application by IP Australia, achieving successful examination of a patent on its lead asset, an HK-4 Glucokinase Activator which targets a wide range of autoimmune diseases. Conduit believes it is more likely to receive subsequent approvals in other markets. Through innovative solid-form technology, Conduit’s R&D team identified cocrystals of its lead asset, AZD1656, a HK-4 Glucokinase Activator which offers promising solutions across a broad range of autoimmune conditions. “Cocrystals are by their very nature unexpected. Creating these cocrystals and obtaining meaningful patent protection for them, highlight the expertise and strategic effectiveness of Conduit's science and approach to drug products,” according to Jeffrey A. Lindeman, Ph.D., the Company’s consultant on cocrystal intellectual property. The stock traded up over 50% in the pre-market in reaction to the news. The $0.40 area acted as support in the pre-market and will be an important level to watch. Above it, targets to the upside are $0.43, $0.47, $0.49, $0.50 and then the pre-market high at $0.5393. Beyond that, $0.60, $0.80 and $1 come into play. Below $0.40, targets to the downside are $0.35, $0.30 and then a gap fill at $0.24. MINI OPTIONS BOOT CAMP TONIGHT @ 7PM ET 💥LIVE W/JEFF WILLIAMS💥 [TAKE YOUR SEAT HERE]( MARKET NEWS 📰 👊 Make sure you are getting my mobile text alerts –  text “RAGE” to 1-(888) 404-5747 to get all of my latest HOT STOCK ideas delivered right to your phone (make sure you put the “1” at the front!). Don’t miss out! Questions or concerns about our products? Email [Support@360wallstreet.io]( © Copyright 2022, RagingBull DISCLAIMER: To more fully understand any Ragingbull.com, LLC ("RagingBull") subscription, website, application or other service ("Services"), please review our full disclaimer located at . FOR EDUCATIONAL AND INFORMATION PURPOSES ONLY; NOT INVESTMENT ADVICE. AnyRagingBull Service offered is for educational and informational purposes only and should NOT be construed as a securities-related offer or solicitation, or be relied upon as personalized investment advice. RagingBull strongly recommends you consult a licensed or registered professional before making any investment decision. RESULTS PRESENTED NOT TYPICAL OR VERIFIED. RagingBull Services may contain information regarding the historical trading performance of RagingBull owners or employees, and/or testimonials of non-employees depicting profitability that are believed to be true based on the representations of the persons voluntarily providing the testimonial. However, subscribers' trading results have NOT been tracked or verified and past performance is not necessarily indicative of future results, and the results presented in this communication are NOT TYPICAL. Actual results will vary widely given a variety of factors such as experience, skill, risk mitigation practices, market dynamics and the amount of capital deployed. Investing in securities is speculative and carries a high degree of risk; you may lose some, all, or possibly more than your original investment. RAGINGBULL IS NOT AN INVESTMENT ADVISOR OR REGISTERED BROKER. Neither RagingBull nor any of its owners or employees is registered as a securities broker-dealer, broker, investment advisor(IA), or IA representative with the U.S. Securities and Exchange Commission, any state securities regulatory authority, or any self-regulatory organization. WE MAY HOLD SECURITIES DISCUSSED. RagingBull has not been paid directly or indirectly by the issuer of any security mentioned in the Services except possibly by advertisers mentioned in this email. However, Ragingbull.com, LLC, its owners, and its employees may purchase, sell, or hold long or short positions in securities of the companies mentioned in this communication. *Sponsored Content: If you purchase anything through a link in this email other than RagingBull services, you should assume that we have an affiliate relationship with the company providing the product or service that you purchase, and that we will be paid in some way. We recommend that you do your own independent research before purchasing anything. We believe in the companies we form affiliate relationships with, but please don’t spend any money on these products or services unless you believe they will help you achieve your goals. RagingBull.com, LLC shall be entitled to recover attorneys’ fees, costs and disbursements. In the event that any suit or action is instituted as a result of doing business with RagingBull.com, LLC and/or its affiliates or if any suit or action is necessary to enforce or interpret these Terms of Service, RagingBull.com, LLC shall be entitled to recover attorneys’ fees, costs and disbursements in addition to any other relief to which it may be entitled. [tw]( Update your email preferences or unsubscribe [here]( © 2024 360 WallStreet 62 Calef Hwy. #233 lee, NH 03861, United States of America [Terms of Service](